Flotetuzumab (INN;[1] development code MGD006) is a bispecific antibody[2] designed for the treatment of acute myeloid leukemia.[3][4]
| Monoclonal antibody | |
|---|---|
| Type | Di-single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | CD3, CD123 |
| Clinical data | |
| Other names | MGD006 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2618H4040N704O813S16 |
| Molar mass | 58898.19 g·mol−1 |
This drug is being developed by MacroGenics, Inc.[5]
References
edit- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- ^ Guy DG, Uy GL (October 2018). "Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia". Curr Hematol Malig Rep. 13 (6): 417–425. doi:10.1007/s11899-018-0472-8. PMC 6295344. PMID 30280288.
- ^ Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE (June 2018). "Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity". Clin. Cancer Res. 24 (11): 2631–2641. doi:10.1158/1078-0432.CCR-17-2265. PMID 29463552..
- ^ Assi R, Kantarjian H, Ravandi F, Daver N (March 2018). "Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors". Curr. Opin. Hematol. 25 (2): 136–145. doi:10.1097/MOH.0000000000000401. PMID 29206680. S2CID 23901088.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |